Now more than ever, 30 million Americans living with a range of 7000 rare or orphan diseases require a high level of therapy adherence support.
Donovan Quill, President and CEO, Optime Care
Advertisement
Articles by Donovan Quill, President and CEO, Optime Care
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
The Emergence of CGRP-Targeted Therapies is Transforming Migraine Care | NCPA 2025
2
Meaningful Recognition: What Pharmacy Technicians Really Want on World Pharmacy Technician Day
3
Pharmacists Improve Patient Health Through Medication Reviews
4
FDA Approves Tezepelumab for as Add-On Treatment for Chronic Rhinosinusitis With Nasal Polyps
5
